Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

LVAD programme in Singapore shows success in advanced heart failure

Christina Lau
23 Jan 2020
Ms Ka-Lee Kerk

Left ventricular assist devices (LVADs) improve survival and quality of life (QoL) in patients with advanced heart failure (HF). At the National Heart Centre Singapore (NHCS), a mechanical cardiac support (MCS) programme in place since 2001 has shown a 2-year survival rate of 100 percent with the use of continuous flow pumps.

“LVADs are increasingly used in patients with advanced HF as a bridge to [heart] transplantation [BTT] or bridge to recovery [BTR]. In clinical trials, QoL improvements were seen as early as 1–3 months after LVAD implantation and were sustained throughout the duration of LVAD support,” said Ms Ka-Lee Kerk, cardiothoracic operating theatre nurse and VAD coordinator at NHCS. [Circulation 2012;126:866-874] “In the 2-year ROADMAP study, better survival with improved functional status was observed in patients on LVAD compared with those on optimal medical management. LVAD also provided improvement in health status among patients with low self-reported health-related QoL.” [JACC Heart Fail 2017;5:518-527; Circ Heart Fail 2017, doi: 10.1161/CIRCHEARTFAILURE.116.003910]

“At NHCS, an MCS programme has been in place to provide BTT or BTR since 2001. We also have an ongoing pilot project of MCS as destination therapy [DT] since 2012, funded by the Ministry of Health,” said Kerk.

Between May 2009 and September 2019, 104 patients (mean age, 51 years) had received continuous flow pumps at NHCS as BTT (n=65) or DT (n=29). “The 2-year survival rate was 100 percent. The median and longest duration of support was 2.9 years and 10.4 years, respectively, after a total follow-up period of 302 patient-years,” reported Kerk. “Thirty-two patients were successfully bridged to heart transplantation, while two were bridged to recovery.”

Among the 104 patients, the most common diagnosis was dilated cardiomyopathy (DCMP; n=46), followed by ischaemic CMP (n=35) and acute coronary syndrome (n=14). After the implantation procedure, all patients were discharged home with the device, with the exception of eight cases of perioperative mortality. The median duration of hospital stay and ICU stay was 29 days and 7 days, respectively.

“A successful LVAD programme requires funding, a dedicated multidisciplinary team with expertise in areas of support services, the use of complementary devices, availability of a referral base and adequate outpatient support, as well as longitudinal care and follow-up,” concluded Kerk. “Education and support are key for successful outpatient support.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.